lapatinib has been researched along with Left Ventricular Dysfunction in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, MJ; Choi, HD | 1 |
| Byrne, J; Ewer, MS; Koehler, M; Perez, EA; Preston, AJ; Rappold, E | 1 |
| Fowler, MB; Telli, ML; Witteles, RM | 1 |
| Criscitiello, C; de Azambuja, E; de Castro, G; Diaz, M; La Gerche, A; Metzger-Filho, O; Piccart-Gebhart, MJ; Saini, KS | 1 |
3 review(s) available for lapatinib and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Cardiac toxicities of lapatinib in patients with breast cancer and other HER2-positive cancers: a meta-analysis.
Topics: Antineoplastic Agents; Breast Neoplasms; Cardiotoxicity; ErbB Receptors; Female; Heart; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Ventricular Dysfunction, Left | 2017 |
Chemotherapy-associated cardiotoxicity: how often does it really occur and how can it be prevented?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Pharmacological; Cardiac Imaging Techniques; Cardiotoxins; Clinical Trials as Topic; Drug Monitoring; Humans; Lapatinib; Neoplasms; Outcome and Process Assessment, Health Care; Protein Kinase Inhibitors; Quinazolines; Severity of Illness Index; Trastuzumab; Ventricular Dysfunction, Left | 2011 |
Targeted therapies in breast cancer: are heart and vessels also being targeted?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Female; Heart Failure; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Trastuzumab; Ventricular Dysfunction, Left | 2012 |
1 other study(ies) available for lapatinib and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Clinical Trials as Topic; Female; Heart Failure; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Stroke Volume; Ventricular Dysfunction, Left | 2008 |